NCT04134312: A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have disease progression after first line chemotherapy (TNBC), 2 lines of hormonal therapy & 1 chemotherapy regimen (HR+), & 2 Her2-targeted treatment regimens (HER2+)
Exclusions: Patients with known untreated unstable metastatic disease to the central nervous system – see trial for details

Comments are closed.

Up ↑